James Weissman joins Dicerna Pharmaceuticals as CBO
This article was originally published in Scrip
Dicerna Pharmaceuticals, a private, venture-backed RNAi-focused biopharmaceutical company developing novel therapeutic agents and related drug delivery systems in oncology and other disease areas, has appointed James Weissman chief business officer. Mr Weissman joins Dicerna from MannKind Corporation where he was vice-president of business development, and previously held business development and marketing positions at Pfizer.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.